Corcept Therapeutics (CORT) closed the last trading session at $34.94, gaining 5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $59.60 indicates a 70.6% upside potential. The average comprises five short-term price targets ranging from a low of $38 to a high of $78, with a standard deviation of $17.33. While the lowest estimate indicates an increase of 8.8% from the current price ...

Have you been paying attention to shares of Corcept Therapeutics (CORT) ? Shares have been on the move with the stock up 26.8% over the past month. The stock hit a new 52-week high of $39.75 in the previous session. Corcept Therapeutics has gained 19.1% since the start of the year compared to the 7.1% move for the Zacks Medical sector and the -1.9% return for the Zacks Medical - Drugs industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't misse ...

Corcept Therapeutics (CORT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drug developer, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings esti ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

Corcept Therapeutics Overview For some background: The conflict between Corcept and Teva revolves around Corcept's Cushing's drug, Korlym, which was first approved in 2012. After the drug enjoyed several years of orphan drug exclusivity, Teva filed an ANDA in 2018 for a generic version, prompting a legal dispute. The dispute is regarding a couple of Corcept's key patents, particularly U.S. Patents 10,195,214 and 10,842,800, that cover methods of safely administering Korlym with CYP3A4 inhibitors. In late De ...

Corcept Therapeutics Incorporated (CORT) reported second-quarter 2024 earnings of 32 cents per share, which beat the Zacks Consensus Estimate of 23 cents. The company had reported earnings of 25 cents per share in the year-ago quarter. Quarter in Detail Research and development expenses surged 35.5% year over year to $58.7 million. Consequently, operating expenses increased to $128.2 million, up 45.5% from the year-ago quarter's level, owing to higher expenses related to ongoing clinical studies and support ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - T ...

This quarterly report represents an earnings surprise of 39.13%. A quarter ago, it was expected that this drug developer would post earnings of $0.21 per share when it actually produced earnings of $0.25, delivering a surprise of 19.05%. Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $163.8 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 6.41%. This compares to year-ago revenues of $117.72 million. The company has topped consensus revenue ...

There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2023. Melucci Litigation and Settlement On April 12, 2024, we entered into a six-year sublease (the "Sublease") with Zuora, Inc. for office space located at 101 Redwood Shores Parkway, Redwood City, California, effective from July 1, 2024. The leased property will serve as our new headquarters effective August 1, 2024. The portion of the premises sub ...

MENLO PARK, Calif., (July 29, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. • Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 million "Once again, we had a record number of new Korlym® prescribers ...